Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.

Oncotarget · 2014 · PMC4147342 · PMID 24980831

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

The concentration of another pro-inflammatory cytokine, TNF-α, showed a borderline significant down-modulation after combination treatment as compared to control group (KWT Bonferroni adjusted P -value: 0.08, Figure 4B ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.